...
【24h】

Treatment and prognostic factors of papillary thyroid microcarcinoma.

机译:甲状腺乳头状微癌的治疗和预后因素。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To discuss the prognostic factors and outcomes of treatment in patients diagnosed with papillary thyroid microcarcinoma. DESIGN: Retrospective observational case review. SETTING: Department of Otorhinolaryngology of the tertiary referral teaching hospital of Parma. PARTICIPANTS: Ninety-seven patients diagnosed with PTMC and surgically treated between January 1998 and December 2007. MAIN OUTCOME MEASURES: Clinical and histopathological characteristics of the study group were identified and statistically analysed. RESULTS: No cancer-related deaths were registered. Incidence of recurrent disease was 9% after a 43 month mean follow-up (range 12-120). Univariate analysis detected that metastases in neck lymph nodes at diagnosis (p = 0.025), a tumour >5 mm in size (p = 0.011), the presence of bilateral tumoural foci (p = 0.007), the presence of capsular invasion (p = 0.001), and the presence of vascular invasion (p = 0.004) were related to recurrent disease. On multivariate analysis, the presence of bilateral tumoural foci (p = 0.030), and the presence of capsular invasion (p = 0.005) were significantly related to tumour recurrence. CONCLUSION: The prognosis for patients with papillary thyroid microcarcinoma in this series was excellent, with a 100% survival rate and minimal surgical-related morbidity. Nevertheless, approximately 10% of patients developed recurrent disease; aggressive treatment may be justified depending on the presence or absence of prognostic risk factors.
机译:目的:探讨甲状腺乳头状微癌患者的预后因素和治疗结果。设计:回顾性观察病例回顾。单位:帕尔马第三级转诊教学医院耳鼻咽喉科。参加者:1998年1月至2007年12月,经诊断为PTMC并经手术治疗的97例患者。主要观察指标:对研究组的临床和组织病理学特征进行鉴定并进行统计学分析。结果:未发现与癌症相关的死亡。平均随访43个月(范围12-120),复发疾病的发生率为9%。单因素分析检测到诊断时发现颈部淋巴结转移(p = 0.025),肿瘤大小> 5 mm(p = 0.011),双侧肿瘤灶存在(p = 0.007),包膜浸润(p = 0.001)和血管浸润(p = 0.004)与复发疾病有关。在多变量分析中,双侧肿瘤灶的存在(p = 0.030)和包膜浸润的存在(p = 0.005)与肿瘤复发显着相关。结论:该系列甲状腺乳头状微癌患者的预后良好,生存率100%,与手术相关的发病率极低。然而,大约有10%的患者会复发。根据是否存在预后风险因素,积极治疗可能是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号